Royalty Exchange
Back to Marketplace

Listing 6616

Connecting to live updates

Listerine Royalties in Perpetuity

Artwork for Listerine Royalties in Perpetuity
    • Listerine
    • …

    Offers

    List Price

    —

    Open OfferHighest Open Offer

    —

    This listing doesn't have a list price.

    Listing Insights

    Marketplace Median

    —

    Owner Last Active

    —

    Final Auction

    Liquidity Pool

    —

    Listing Tools

    Price Tracker

    4 offers made by 4 buyers

    • List price
    • Closed
    • Open

    Offer History

    • $480,000

      Buyer 4 made 149 days ago

    • $475,420

      Buyer 3 made 232 days ago

    • $475,001

      Buyer 2 made 235 days ago

    • $475,000

      Buyer 1 made 237 days ago

    About

    $57,460
    3-Year Average
    $59,663
    Earnings Since 1993
    $1,507,029
    145.25 Years
    Work Included
    1
    —
    $1,000,000
    Owner Last Active
    —
    Last Transaction Price
    $1,035,000
    Last Transaction Date
    Oct 3, 2024October 3, 2024
    Next Statement Update
    3 days (Nov 16, 2026November 16, 2026)
    Life of Rights
    Learn more about rights and royalties

    Earning statistics last updated

    Sale History

    • 10/2024 $1,035,000.00 (16.01x) - Listing #5711

    Other Information

    This is a unique asset with a 144-year earning history of monthly payments for gross sales of Listerine Antiseptic. This royalty income is derived from what has been called one of the most remarkable business transactions in U.S. business history. As the winning bidder, you’ll own a royalty interest in the gross global sales of Listerine Antiseptic mouthwash. 

    What is Being Sold. A royalty interest in the gross sales of Listerine Antiseptic. The royalty interest is derived from an 1881 agreement between the inventor of the Listerine formula and the original distributor of the Listerine product. The royalty agreement calls for a flat rate royalty on worldwide Listerine sales, for as long as Listerine is sold. The agreement has been in effect since 1881, and in 1959, its perpetual nature was upheld in U.S. federal court.

    About the Asset. In 1879, Dr. JJ Lawrence invented Listerine and in 1881, licensed the secret formula to J.W. Lambert and Lambert Pharmaceutical Co., ultimately settling on a royalty based on the number of ounces sold, to be paid to him and his “heirs, executors, or assigns” for as long as Listerine was sold.

    For the next 75 years, the Lawrence family collected these royalties, with the ownership stake splintering between various heirs, some of whom sold portions of their stake to additional owners (such as New York real estate broker John J. Reynolds, who acquired half of the share of these royalties from the Lawrence heirs in 1950). 

    After Lambert Pharmaceutical merged with Warner-Hudnut in 1955, the newly merged management contested the $1.5 million a year they were paying in royalties in court… a case they famously lost in a decision that remains cited in contract law cases and classes today. 

    As a result of this decision, the Listerine royalty payments will remain in force for the lifetime of the brand, paid to whoever owns a share. Today, those entities include not only the heirs of the Lawrence family but also various pension funds, universities, hospitals, and multiple individuals. 

    Domestic production of Listerine is done in Pennsylvania, while according to Volza, the rest of the world primarily imports from Colombia, Thailand and India. 

    Payment Schedule. U.S.-generated royalties are paid monthly, based on the prior month’s sales. Royalties from sales in all other countries are paid on a quarterly basis. These sales royalties are calculated on the gross sales of Listerine Antiseptic by Kenvue (previously Johnson & Johnson).

    You’ll notice a spike in payments in the last month of every quarter (March, June, September, and December) due to the quarterly foreign royalty payments.  A split of foreign royalties was not reported by Kenvue starting in June 2023 -March 2025, as a result, the breakout is estimated based on the average historical reporting at 70% International and 30% Domestic in those payment months. This breakout was reported in June 2025 and forward.

    Financials

    Earnings By Period

    Monthly, as statements report

    • Domestic
    • International
    • Unreported
    • Net
    Year20222023202420252026*
    Earnings$62,937$62,877$62,603$57,176$43,333

    * 2026 earnings have not been paid for the entire year. The winning buyer will receive the remaining earnings for the year.


    Income Types

    Income TypesEarningsShare
    Other$57,460100%

    * Historic royalty income does not guarantee future royalty income. Future royalty income depends upon future sales and licensing revenue generated by the intellectual property associated with this listing. All earnings analysis and investment decisions are investors’ sole responsibility per Royalty Exchange’s Terms of Use.

    Included Works

    Please refer to the Other Information section to download the full works list.